Business Wire

Global Rosacea Pipeline Drugs in Development, 2021 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Rosacea (Dermatology) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.

The pipeline guide provides comprehensive information on the therapeutics under development for Rosacea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The guide also reviews of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 10, 6, 1 and 9 respectively.

The pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Report Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rosacea (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Rosacea (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rosacea (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rosacea (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rosacea (Dermatology)

Companies Mentioned

  • Accuitis Pharmaceuticals Inc
  • AiViva BioPharma Inc
  • Alfasigma SpA
  • Amgen Inc
  • AOBiome LLC
  • Attillaps Holdings Inc
  • Biomimetix JV LLC
  • Botanix Pharmaceuticals Ltd
  • Cellix Bio Pvt Ltd
  • Cutanea Life Sciences Inc
  • Dermata Therapeutics Inc
  • ELORAC Inc
  • Emeriti Pharma AB
  • Evommune Inc
  • Hovione FarmaCiencia SA
  • Maruho Co Ltd
  • Matrisys Bioscience Inc
  • Perpetuum BV
  • Promius Pharma LLC
  • Sol-Gel Technologies Ltd
  • Sunny Pharmtech Inc
  • Tarsus Pharmaceuticals Inc
  • Timber Pharmaceuticals Inc
  • TWi Biotechnology Inc
  • Union Therapeutics AS
  • VYNE Therapeutics Inc

Key Topics Covered:

  • Rosacea – Overview
  • Rosacea – Therapeutics Assessment
  • Rosacea – Companies Involved in Therapeutics Development
  • Rosacea – Drug Profiles
  • Rosacea – Dormant Projects
  • Rosacea – Discontinued Products
  • Rosacea – Product Development Milestones

For more information about this report visit https://www.researchandmarkets.com/r/x0nqxj

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Comment moderation is enabled. Your comment may take some time to appear.

Back to top button

Adblock detected

Please consider supporting us by disabling your ad blocker